Galapapositief schreef op 25 november 2020 14:54:
Ugh, Ik heb een reactie van Mandy maar kan niet zeggen dat ik helemaal tevreden ben:
It is my current understanding that the launch of Versalab wasn't material enough to be in a RNS yesterday, correct? I've seen the launch on twitter, but just wondering the following.
1: I've googled the Versalab and without the covid addition in the search-term I couldn't find any of it. With the covid-addition my first hit was the tweet of the Primerdesign-account. The second hit was the Novacyt insider website. This got me questioning what the current impact of this launch is. Will there be any marketing? How are you making sure that the world knows about this (innovative) solution?
2: Is the outlook given in september (150 million revenue) changed materially enough to update or is this outlook still correct and will the company finish 2020 with no significant change revenue?
With the constant-falling SP, many private investors are reconsidering their position, including myself. But I would like to make my consideration with all the information I could possibly find. Everyone knows that testing is not over but the silence - and the missing of RNS with updates on how the company is actually doing - is making people sell and therefore making the drop in SP bigger than it should be.
Thanks in advance for your time and answers
Thank you for your email and continued support.
Correct, the Versalab news was not considered material enough to warrant an RNS and was part of a strategic marketing exercise, hence it not being circulated to investors or translated into French for the website.
We appreciate shareholders frustration with the share price being so volatile at the moment, but would re-iterate the Company will only disclose price sensitive information or material changes to its trading conditions if and when they occur.
Investors have two analyst research notes to review with their projections for Novacyt’s financial performance for 2020 and beyond which are only weeks old – this provides significant, independent analysis on the expected performance of the Company. The outlook has not changed, therefore we have not needed to communicate anything to the market.
I hope that helps.
Corporate and Investor Relations Managermandy.email@example.com
Moet je het dikgedrukte in relatie tot elkaar lezen of niet? Ze verwijst nadrukkelijk naar de cijfers van die analisten ipv te zeggen dat ze vasthoudt aan eigen outlook.